1
|
Khater J, Malakouti S, Khoury AE, Cortese B. Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease. J Cardiovasc Med (Hagerstown) 2024; 25:247-258. [PMID: 38305141 DOI: 10.2459/jcm.0000000000001598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2024]
Abstract
AIMS The use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as a new class of drug in treating type 2 diabetes has expanded beyond its original framework. Positive results have been achieved in reducing symptoms in patients with cardiovascular disease (CVD). The aim of this article is to present an in-depth review of the basic principles of this class of medications and how it has brought benefits to patients affected particularly by heart failure. METHODS Following a thorough PubMed search, this review includes 62 studies published between 2015 and 2023. Keywords searched included 'sodium-glucose cotransporter 2 inhibitors', 'cardiovascular disease', 'heart failure', 'chronic kidney disease', and 'type 2 diabetes'. The most recent and comprehensive data were used. RESULTS Positive results have been achieved in reducing symptoms in patients with CVD. SGLT2 inhibitors have also been shown to be useful in other contexts such as nonalcoholic fatty liver disease (NAFLD) by reducing liver fat accumulation, kidney benefits by improving body weight and vascular endothelium, improving eGFR, and reducing progression to end stage kidney disease (ESKD). SGLT2 inhibitors are also effective in reducing the need for heart failure hospitalizations and the risk of serious cardiac adverse events, including cardiovascular and all-cause mortality, in patients with reduced or preserved left ventricular (LV) ejection fraction and in acute or decompensated settings. CONCLUSION SGLT2 inhibitors have evolved into metabolic drugs because of their multisystem action and are indicated for the treatment of all spectrums of heart failure, type 2 diabetes, and chronic kidney disease.
Collapse
Affiliation(s)
- Jacinthe Khater
- DCB Academy, Milan, Italy
- Faculty of Medical Sciences, Lebanese University Rafic Hariri University Campus Hadath
| | | | - Antoine El Khoury
- DCB Academy, Milan, Italy
- Department of Cardiology, Faculty of Medicine and Medical Sciences, University of Balamand, Beirut, Lebanon
| | - Bernardo Cortese
- DCB Academy, Milan, Italy
- Fondazione Ricerca e Innovazione Cardiovascolare, Milan, Italy
| |
Collapse
|
2
|
Giovannico L, Parigino D, Ramirez AD, Fischetti G, Santeramo V, Savino L, Fiore G, Bottio T, Musajo Somma C, Gesualdo L, Milano AD. World's oldest heart transplant donor: age is just a number. J Cardiovasc Med (Hagerstown) 2024; 25:243-245. [PMID: 38305142 DOI: 10.2459/jcm.0000000000001585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2024]
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Loreto Gesualdo
- Nephrology, Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Medical School, Piazza Giulio Cesare 11, Bari, Italy
| | | |
Collapse
|
3
|
Aimo A, Teis A, Kasa G, Juncà G, Lupón J, Domingo M, Ferrer E, Vallejo N, Cediel G, Codina P, López-Ayerbe J, Georgiopoulos G, Martini N, Emdin M, Bayes-Genís A, Rapezzi C, Delgado V. Left-to-right ventricular volume ratio and outcome in heart failure with preserved ejection fraction. J Cardiovasc Med (Hagerstown) 2023; 24:552-560. [PMID: 37409600 DOI: 10.2459/jcm.0000000000001500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/07/2023]
Abstract
BACKGROUND Age-specific and gender-specific reference values for left ventricular (LV) and right ventricle volumes are available. The prognostic implications of the ratio between these volumes in heart failure and preserved ejection fraction (HFpEF) have never been evaluated. METHODS We examined all HFpEF outpatients undergoing a cardiac magnetic resonance from 2011 to 2021. The left-to-right ventricular volume ratio (LRVR) was defined as the ratio between the LV and right ventricle end-diastolic volume indexes (LVEDVi/RVEDVi). RESULTS Among 159 patients [median age 58 years (interquartile range 49-69), 64% men, LV ejection fraction 60% (54-70%)] the median LRVR was 1.21 (1.07-1.40). Over 3.5 years (1.5-5.0), 23 patients (15%) experienced all-cause death or heart failure hospitalization, and 22 (14%) cardiovascular death or heart failure hospitalization. The risk of all-cause death or heart failure hospitalization increased with an LRVR less than 1.0 or at least 1.4. An LRVR less than 1.0 was associated with a higher risk of all-cause death or heart failure hospitalization [hazard ratio 5.95, 95% confidence interval (CI) 1.67-21.28; P = 0.006] and cardiovascular death or heart failure hospitalization (hazard ratio 5.68, 95% CI 1.58-20.35; P = 0.008) as compared with LRVR 1.0-1.3. Furthermore, an LRVR at least 1.4 was associated with a higher risk of all-cause death or heart failure hospitalization (hazard ratio 4.10, 95% CI 1.58-10.61; P = 0.004) and cardiovascular death or heart failure hospitalization (hazard ratio 3.71, 95% CI 1.41-9.79; P = 0.008) as compared with LRVR 1.0-1.3. These results were confirmed in patients without dilation of either ventricle. CONCLUSION LRVR values less than 1.0 or at least 1.4 are associated with worse outcomes in HFpEF. LRVR may become a valuable tool for risk prediction in HFpEF.
Collapse
Affiliation(s)
- Alberto Aimo
- Scuola Superiore Sant'Anna
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy
| | - Albert Teis
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
| | - Gizem Kasa
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
| | - Gladys Juncà
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
| | - Josep Lupón
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
| | - Mar Domingo
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
| | - Elena Ferrer
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
| | - Nuria Vallejo
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
| | - Germán Cediel
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
| | - Pau Codina
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
| | | | - Georgios Georgiopoulos
- Scuola Superiore Sant'Anna
- King's College, London, UK
- Cardiology Centre, University of Ferrara, Ferrara
| | - Nicola Martini
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy
| | - Michele Emdin
- Scuola Superiore Sant'Anna
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy
| | - Antoni Bayes-Genís
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
- CIBERCV, Carlos III Institute of Health, Madrid
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Claudio Rapezzi
- King's College, London, UK
- Cardiology Centre, University of Ferrara, Ferrara
- Maria Cecilia Hospital, GVM Care & Research, Cotignola (Ravenna), Italy
| | - Victoria Delgado
- Heart Institute, Hospital University Germans Trias i Pujol, Badalona
- Department of Cardiology, Leiden University Medical Center, the Netherlands
| |
Collapse
|
4
|
Muacevic A, Adler JR. The Importance of Diaphragmatic Function in Neuromuscular Expression in Patients With Chronic Heart Failure. Cureus 2023; 15:e34629. [PMID: 36751571 PMCID: PMC9899102 DOI: 10.7759/cureus.34629] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/04/2023] [Indexed: 02/05/2023] Open
Abstract
Chronic heart failure (CHF) is a set of symptoms and physical manifestations caused by the inability of the heart to perform its normal contractile function and satisfy the blood needs of all organs. This dysfunction leads to a non-physiological adaptation of all body systems, including the skeletal muscles and the diaphragm. The myopathy found in patients brings symptoms such as fatigue and intolerance to exercise, with an entity not always attributable to cardiac function. Neuromuscular incoordination is one of the symptoms related to CHF, causing an increased risk of mortality and hospitalization. The article reviews diaphragmatic adaptation in the presence of CHF and seeks to emphasize the importance of the diaphragm in understanding skeletal muscle incoordination in patients.
Collapse
|